Article info

Download PDFPDF
Extended report
Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

Authors

  1. Correspondence to Dr Jaap Fransen, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Huispost 470, Postbus 9101, Nijmegen 6500 HB, The Netherlands; J.Fransen{at}reuma.umcn.nl
View Full Text

Citation

van Dartel SAA, Fransen J, Kievit W, et al
Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

Publication history

  • Received January 13, 2012
  • Accepted July 3, 2012
  • First published August 11, 2012.
Online issue publication 
May 10, 2013

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.